The Ventinova journey begins with the founding of Dolphys. The company started by developing a drug delivery system. A few years later the idea of manual ventilator Ventrain was born.

Dirk van Asseldonk (left) is a successful entrepreneur, especially interested in ideas at the intersection of technology, medicine and economics. He thinks it is important to do business in markets that really matter, such as a medical innovation that is life-saving.  He met Prof. Dr. med. Enk for the first time in 2007 because Dolphys developed a drug release implant, of which Maastricht University Medical Center (MUMC)  in The Netherlands was a partner. Prof. Dr. med. Dietmar Enk, at the time anesthesiologist at MUMC, is responsible for several inventions. He wanted to be more involved in the development of his inventions and found a suitbale partner in Ventinova Medical (back then Dolphys). In 2008 Dietmar and Dirk started the further development of manual ventilator Ventrain.

Nomination Herman Wijffels Innovatie Prijs
In 2008 Dirk van Asseldonk was nominated for the Rabobank Herman Wijffels Innovatie Prijs with ActivJet, the precursor to Ventrain. This Dutch Herman Wijffels Innovation Prize aims for sustainable innovations.

Collaboration starts with Prof. Dr. Med. Dietmar Enk.

 

In 2013 we enter a new period: Ventinova Medical is founded. The name is a composition of venti (ventilation) and nova (new). 

Unique ventilation method FCV^® is presented by Prof. Dr. med. Dietmar Enk at Euroanaesthesia 2015.

 

Ventinova receives 1.9 million Euros funding from the European Union’s Horizon 2020 research and innovation programme.
The development of mechanical ventilator Evone starts.

Ventinova receives 1.9 million Euros funding from the European Union’s Horizon 2020 research and innovation programme.

CE marking of Evone

 

 

 

 

 

Industry Symposium Euroanaesthesia 2017
Ventinova Medical organized a crowded Industry Symposium at Euroanaesthesia 2017 on the Update and new perspectives in airway management and mechanical ventilation.  Prof. Dr. Carin Hagberg, UT MD Anderson Cancer Center, Houston USA, Prof. Dr. Luciano Gattinoni, University of Goettingen, Germany and Prof. Dr. med. Dietmar Enk, University Hospital of Muenster, Germany, gave their vision on the subject.

 

First clinical in human use of Evone
First clinical in human use of Tritube

 

 

 

 

CE marking of Evone

 

 

 

 

 

Industry Symposium Euroanaesthesia 2017
Ventinova Medical organized a crowded Industry Symposium at Euroanaesthesia 2017 on the Update and new perspectives in airway management and mechanical ventilation.  Prof. Dr. Carin Hagberg, UT MD Anderson Cancer Center, Houston USA, Prof. Dr. Luciano Gattinoni, University of Goettingen, Germany and Prof. Dr. med. Dietmar Enk, University Hospital of Muenster, Germany, gave their vision on the subject.

 

First clinical in human use of Evone
First clinical in human use of Tritube

 

 

 

 

Ventinova’s first Evone is sold to Amsterdam University Medical Center, The Netherlands.

Evone is already used in more than 40 hospitals in 11 countries during a wide variety of surgeries.

Preclinical study in pigs comparing FCV^® to PCV ventilation
Cinematic CT scan after 10 h ventilation, pilot study 10/2018 – 01/2019. Universitätsklinikum Innsbruck.
FCV is on the right.

 

Prof. Dr. med. Christian Byhahn, University Hospital Oldenburg, Germany is very proud to be the owner of ventilator Evone (left on the photo)

Hamad Medical Corporation (HMC) Qatar: the first to introduce Evone in their daily clinical practice in the Middle East 
The anesthesiology team led by Prof. Dr. Marco Marcus achieved regional recognition for their fantastic work done, not only in clinic but even more in setting up an airway management training center, in which Evone with its FCV® technology and the associated ultra-thin Tritube play an important role. Doctors Nabil Shallik and Marcus Lance value the experienced surgical benefits of this “only ventilation appliance of its type”. Furthermore, they acknowledge that Evone may considerably reduce the number of lung complications related to conventional artificial ventilation. They state that “The technology has the potential to be used in various fields of surgery.”